188 related articles for article (PubMed ID: 25698658)
41. Rifaximin in the treatment of recurrent Clostridium difficile infection.
Mattila E; Arkkila P; Mattila PS; Tarkka E; Tissari P; Anttila VJ
Aliment Pharmacol Ther; 2013 Jan; 37(1):122-8. PubMed ID: 23095030
[TBL] [Abstract][Full Text] [Related]
42. Presence of multiple Clostridium difficile strains at primary infection is associated with development of recurrent disease.
Seekatz AM; Wolfrum E; DeWald CM; Putler RKB; Vendrov KC; Rao K; Young VB
Anaerobe; 2018 Oct; 53():74-81. PubMed ID: 29859301
[TBL] [Abstract][Full Text] [Related]
43. A prospective study of community-associated Clostridium difficile infection in Kuwait: Epidemiology and ribotypes.
Jamal W; Pauline E; Rotimi V
Anaerobe; 2015 Oct; 35(Pt B):28-32. PubMed ID: 26144314
[TBL] [Abstract][Full Text] [Related]
44. Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors.
Debast SB; Vaessen N; Choudry A; Wiegers-Ligtvoet EA; van den Berg RJ; Kuijper EJ
Clin Microbiol Infect; 2009 May; 15(5):427-34. PubMed ID: 19416295
[TBL] [Abstract][Full Text] [Related]
45. Clostridium difficile Infection in travelers--a neglected pathogen?
Neuberger A; Saadi T; Shetern A; Schwartz E
J Travel Med; 2013; 20(1):37-43. PubMed ID: 23279229
[TBL] [Abstract][Full Text] [Related]
46. Analysis of prevalence, risk factors and molecular epidemiology of Clostridium difficile infection in Kuwait over a 3-year period.
Jamal W; Rotimi VO; Brazier J; Duerden BI
Anaerobe; 2010 Dec; 16(6):560-5. PubMed ID: 20887795
[TBL] [Abstract][Full Text] [Related]
47. Clostridium difficile infection in the "oldest" old: clinical outcomes in patients aged 80 and older.
Cober ED; Malani PN
J Am Geriatr Soc; 2009 Apr; 57(4):659-62. PubMed ID: 19392957
[TBL] [Abstract][Full Text] [Related]
48. Molecular typing and epidemiology of Clostridium difficile in respiratory care wards of central Taiwan.
Wei HL; Wei SH; Huang CW; Shih CH; Huang YW; Lu MC; Hsu JC; Liou YS; Chiou CS
J Microbiol Immunol Infect; 2015 Feb; 48(1):65-71. PubMed ID: 23726464
[TBL] [Abstract][Full Text] [Related]
49. Multihospital outbreak of Clostridium difficile ribotype 027 infection: epidemiology and analysis of control measures.
Aldeyab MA; Devine MJ; Flanagan P; Mannion M; Craig A; Scott MG; Harbarth S; Vernaz N; Davies E; Brazier JS; Smyth B; McElnay JC; Gilmore BF; Conlon G; Magee FA; Elhajji FW; Small S; Edwards C; Funston C; Kearney MP
Infect Control Hosp Epidemiol; 2011 Mar; 32(3):210-9. PubMed ID: 21460505
[TBL] [Abstract][Full Text] [Related]
50. A case of imported Clostridium difficile PCR-ribotype 027 infection within the Czech Republic which has a high prevalence of C. difficile ribotype 176.
Krutova M; Nyc O; Kuijper EJ; Geigerova L; Matejkova J; Bergerova T; Arvand M
Anaerobe; 2014 Dec; 30():153-5. PubMed ID: 25300750
[TBL] [Abstract][Full Text] [Related]
51. Diagnosis and management of Clostridium difficile infection.
Dupont HL
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1216-23; quiz e73. PubMed ID: 23542332
[TBL] [Abstract][Full Text] [Related]
52. Is Clostridium difficile infection a risk factor for subsequent bloodstream infection?
Ulrich RJ; Santhosh K; Mogle JA; Young VB; Rao K
Anaerobe; 2017 Dec; 48():27-33. PubMed ID: 28669864
[TBL] [Abstract][Full Text] [Related]
53. Morbidity and mortality associated with Clostridium difficile ribotype 078: a case-case study.
Patterson L; Wilcox MH; Fawley WN; Verlander NQ; Geoghegan L; Patel BC; Wyatt T; Smyth B
J Hosp Infect; 2012 Oct; 82(2):125-8. PubMed ID: 22947650
[TBL] [Abstract][Full Text] [Related]
54. Clostridioides difficile colonization and infection in patients with newly diagnosed acute leukemia: Incidence, risk factors, and patient outcomes.
Ford CD; Lopansri BK; Webb BJ; Coombs J; Gouw L; Asch J; Hoda D
Am J Infect Control; 2019 Apr; 47(4):394-399. PubMed ID: 30471971
[TBL] [Abstract][Full Text] [Related]
55. Occurrence of Clostridium difficile infections due to PCR ribotype 027 in Bucharest, Romania.
Rafila A; Indra A; Popescu GA; Wewalka G; Allerberger F; Benea S; Badicut I; Aschbacher R; Huhulescu S
J Infect Dev Ctries; 2014 Jun; 8(6):694-8. PubMed ID: 24916866
[TBL] [Abstract][Full Text] [Related]
56. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
Miller M
Expert Opin Pharmacother; 2010 Jun; 11(9):1569-78. PubMed ID: 20446864
[TBL] [Abstract][Full Text] [Related]
57. Vancomycin-resistant Clostridium innocuum bacteremia following oral vancomycin for Clostridium difficile infection.
Hung YP; Lin HJ; Wu CJ; Chen PL; Lee JC; Liu HC; Wu YH; Yeh FH; Tsai PJ; Ko WC
Anaerobe; 2014 Dec; 30():24-6. PubMed ID: 25102472
[TBL] [Abstract][Full Text] [Related]
58. Risk Factors and Outcomes for Bloodstream Infections Secondary to Clostridium difficile Infection.
Falcone M; Russo A; Iraci F; Carfagna P; Goldoni P; Vullo V; Venditti M
Antimicrob Agents Chemother; 2016 Jan; 60(1):252-7. PubMed ID: 26482315
[TBL] [Abstract][Full Text] [Related]
59. A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs.
Le F; Arora V; Shah DN; Salazar M; Palmer HR; Garey KW
Pharmacotherapy; 2012 Feb; 32(2):129-34. PubMed ID: 22392421
[TBL] [Abstract][Full Text] [Related]
60. Use of tigecycline for the management of Clostridium difficile colitis in oncology patients and case series of breakthrough infections.
Brinda BJ; Pasikhova Y; Quilitz RE; Thai CM; Greene JN
J Hosp Infect; 2017 Apr; 95(4):426-432. PubMed ID: 28153556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
